Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Globus Medical ( (GMED) ).
On July 18, 2025, Globus Medical announced leadership changes with Daniel T. Scavilla resigning as President and CEO, and Keith W. Pfeil appointed as his successor. Pfeil, who has been with the company since 2019, previously served as Chief Operating Officer and Chief Financial Officer. Kyle Kline was also appointed as the new Chief Financial Officer. The company reported preliminary second-quarter sales results, showing an 18.4% increase over the previous year, driven by strong performance in the US Spine business. These leadership transitions and sales results indicate a strategic focus on maintaining growth and innovation in the musculoskeletal technology sector.
The most recent analyst rating on (GMED) stock is a Hold with a $77.00 price target. To see the full list of analyst forecasts on Globus Medical stock, see the GMED Stock Forecast page.
Spark’s Take on GMED Stock
According to Spark, TipRanks’ AI Analyst, GMED is a Outperform.
Globus Medical’s strong financial performance and positive corporate events are significant strengths, supporting a solid overall score. However, high valuation concerns and mixed technical indicators temper the outlook. The earnings call highlighted both challenges and opportunities, contributing to a balanced view.
To see Spark’s full report on GMED stock, click here.
More about Globus Medical
Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and advancing care in spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.
Average Trading Volume: 1,537,165
Technical Sentiment Signal: Sell
Current Market Cap: $7.63B
See more insights into GMED stock on TipRanks’ Stock Analysis page.